HOME > BUSINESS > Article

Text Size

small

medium

large


"Deeply Moved" by Birth of Novel Alzheimer's Drug: Eisai CEO

"Deeply Moved" by Birth of Novel Alzheimer's Drug: Eisai CEO

   Tokyo, June 9 (Jiji Press)--Haruo Naito, chief executive officer of Eisai Co. <4523>, said Wednesday he was "deeply moved" by novel Alzheimer's disease drug aducanumab coming into being.
   Eizai and its U.S. partner Biogen Inc. have created the first treatment that works directly on the causal substance for the incurable disease, Naito said in an online briefing session after the U.S. Food and Drug Administration's approval of the drug to slow cognitive decline.

To read a full story, please click here to find out how to subscribe.

BUSINESS

Aomori Tourism Information

HEADLINES

POLITICS
Lockdown Easing in England to Be Delayed by One Month Due to Variant Risk
ECONOMY
Tokyo Stocks (Morning Close): Nikkei Average 29,375.94 (+214.14)
SPORTS
Men's Soccer: Slovakia, Czech Republic Record Wins in Euro 1st Round Matches
OTHER
2 Ospreys of US Military Land at Yamagata Airport Monday without Prior Notice

AFP-JIJI PRESS NEWS JOURNAL


Photos